Who should be tested for elevated Lipoprotein(a) levels?

The European Atherosclerotic Society suggests that Lipoprotein(a) should be measured once in all subjects at intermediate or high risk of CVD or CHD (coronary heart disease) who present with¹:

There are also a number of health conditions that have been linked to elevated levels of Lipoprotein(a) therefore patients affected by the below should also be considered for Lipoprotein(a) monitoring:

As demonstrated by the above, a high proportion of patients could be affected by elevated levels of Lipoprotein(a), making this test an essential addition to the laboratory’s testing panel. Using Randox Lipoprotein(a) will ensure the accurate identification of at risk patients, enabling timely and appropriate intervention to be implemented.

¹Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoglu L, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010; 31(23):2844-53

© 2020 Randox Laboratories Ltd. All rights reserved.